Nuformix (NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announced on Thursday positive trial results for its lead NXP001 programme.
The results confirmed NXP001's potential for development as a treatment for chemotherapy-induced nausea and vomiting (CINV), which the company said comprises one third of global cancer patients.
In a pilot study of healthy subjects, a proprietary cocrystal-based formulation developed within the NXP001 programme demonstrated bioequivalence to Merck's EMEND® at 125mg both in terms of peak exposure and overall exposure.
The results allow the company to trigger a final milestone payment of £2 million from its Chinese licensing partner, Newsummit Biopharma, who have started product registration in China.
Shares in Nuformix were trading 12.98% higher at 11.75p a share following the results
Dr Dan Gooding, CEO, Nuformix plc, said: "The results have positive implications for our NXP001 programme and provide further validation for Nuformix's overall business model.”
He added: “Clinical success with NXP001 demonstrates the potential for our wider pipeline. We now seek to replicate our approach of using known drugs to create value with reduced risk and costs of development to build a wider pipeline of innovative therapies.”
“This will be achieved both with in-house programmes and in other collaborations, such as that announced previously with Ebers.”
Nuformix said it will progress ongoing discussions for licensing rest of world rights to NXP001 for CINV, and finalise further product development opportunities for the NXP001 programme.
It will continue to progress its wider portfolio and identify high-value applications for cocrystal technology.
Follow News & Updates from Nuformix here: